|
Democratizing germline genetic testing and its impact on prostate cancer clinical decision-making. |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer |
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar |
|
|
No Relationships to Disclose |
|
Christopher Michael Pieczonka |
Employment - Associated Medical Professionals of New York |
Leadership - Associated Medical Professionals of New York |
Stock and Other Ownership Interests - US Urology Partners |
Honoraria - AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; Janssen; Merck; Myovant Sciences; Pfizer/Astellas; Sun Pharma |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Merck; Pfizer/Astellas; Sun Pharma; Sun Pharma; Tolmar |
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Foundation Medicine; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sun Pharma |
Research Funding - Advantagene; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Innocrin Pharma; Janssen Oncology; Merck; Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/Merck; Janssen |
|
|
Consulting or Advisory Role - Marinus Pharmaceuticals |
|
|
Honoraria - AstraZeneca; Dendreon; Janssen Oncology; Myriad Genetics; Pfizer/Astellas |
Consulting or Advisory Role - BK Ultrasound |
Speakers' Bureau - Janssen Oncology; Pfizer/Astellas |
|
|
Employment - Convergent Genomics; Urology Austin |
Leadership - Convergent Genomics |
Stock and Other Ownership Interests - Convergent Genomics |
Consulting or Advisory Role - Boston Scientific; Calyxo; IO Urology; Magforce; Neotract; UroDev Medical |
Research Funding - Calyxo; Candel Therapeutics; Convergent Genomics; InVitae; Janssen; MDxHealth; Neotract; Pfizer; Urotronic |
Travel, Accommodations, Expenses - Convergent Genomics; Neotract |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Merck; Clovis Oncology; Decipher Biosciences; Janssen; Myriad Genetics |
|
|
Consulting or Advisory Role - Myriad Genetic Laboratories |
Research Funding - Palette Life Sciences |
|
|
Consulting or Advisory Role - Dendreon; Exact Imaging; Myovant Sciences |
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Exact Imaging; Janssen; Myovant Sciences; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Invitae |
|
|
|
Stock and Other Ownership Interests - Invitae |
|
|
|
Stock and Other Ownership Interests - InVitae |
Consulting or Advisory Role - InVitae |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Genome Medical; Invitae; Maze Therapeutics |
|
Consulting or Advisory Role - Genome Medical; Maze Therapeutics; Pfizer |
Patents, Royalties, Other Intellectual Property - Royalties on a patented mouse model for Parkinson disease held by the National Institutes of Health and the University of California San Francisco |
|
|
|
Stock and Other Ownership Interests - Invitae |